RecruitingNCT06516458
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Development of Camera Based Gait Deviation Index for Persons With Multiple Sclerosis
Sponsor
Shirley Ryan AbilityLab
Enrollment
40 participants
Start Date
Jul 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
- Able to ambulate overground
- Relapse free for at least 1 month
- Age ≥18 and ≤ 75 years
- Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
Exclusion Criteria1
- \- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing
Interventions
DIAGNOSTIC_TESTCamera Based Kinematic Analysis
Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06516458
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location